Literature DB >> 28427510

Central nervous system gliomas.

Michele Reni1, Elena Mazza2, Silvia Zanon2, Gemma Gatta3, Charles J Vecht4.   

Abstract

Evidence-based practical guidelines on diagnosis, prognosis, and treatment on the most frequent adult brain tumours are delineated. In Europe, 27,000 new cases of malignant glial tumours and 1000 new cases of malignant ependymal tumours are diagnosed every year. The most common glial tumours are glioblastoma multiforme and anaplastic glioma, comprising more than 50% and 10%, respectively, of the total gliomas. Prognosis of gliomas is generally poor. Environmental and genetic factors have been correlated with an increased risk of developing brain tumours. Surgical resection represents the first treatment option for all histotypes. Role and timing of radiotherapy and chemotherapy as well as treatment for recurrent/progressive disease should be based on age, performance status, histopathological diagnosis, molecular markers, and previous therapy. Impaired neurocognitive and neuropsychological function is common in long-term survivors, regardless of the histology and grade of the tumour and should be taken into account in treatment planning.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Anaplastic glioma; Brain tumors; Ependymoma; Glioblastoma

Mesh:

Year:  2017        PMID: 28427510     DOI: 10.1016/j.critrevonc.2017.03.021

Source DB:  PubMed          Journal:  Crit Rev Oncol Hematol        ISSN: 1040-8428            Impact factor:   6.312


  43 in total

Review 1.  Highlights of articles published in annals of nuclear medicine 2016.

Authors:  Hossein Jadvar
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-07-28       Impact factor: 9.236

2.  SOX2 immunity and tissue resident memory in children and young adults with glioma.

Authors:  Juan C Vasquez; Anita Huttner; Lin Zhang; Asher Marks; Amy Chan; Joachim M Baehring; Kristopher T Kahle; Kavita M Dhodapkar
Journal:  J Neurooncol       Date:  2017-06-15       Impact factor: 4.130

Review 3.  The MYC Enhancer-ome: Long-Range Transcriptional Regulation of MYC in Cancer.

Authors:  Olga Lancho; Daniel Herranz
Journal:  Trends Cancer       Date:  2018-11-02

Review 4.  Translational gap in ongoing clinical trials for glioma.

Authors:  Alecia Florence Guishard; Juan Sebastian Yakisich; Neelam Azad; Anand Krishnan V Iyer
Journal:  J Clin Neurosci       Date:  2017-10-21       Impact factor: 1.961

5.  Function of neuronal nitric oxide synthase enzyme in temozolomide-induced damage of astrocytic tumor cells.

Authors:  Fernando Francisco Borges Resende; Simoneide Souza Titze-de-Almeida; Ricardo Titze-de-Almeida
Journal:  Oncol Lett       Date:  2018-02-01       Impact factor: 2.967

6.  Prognostic value of the Glasgow Prognostic Score for glioblastoma multiforme patients treated with radiotherapy and temozolomide.

Authors:  Erkan Topkan; Ugur Selek; Yurday Ozdemir; Berna A Yildirim; Ozan C Guler; Fuat Ciner; Huseyin Mertsoylu; Kadir Tufan
Journal:  J Neurooncol       Date:  2018-04-25       Impact factor: 4.130

7.  Soluble cytotoxic T-lymphocyte-associated antigen 4 (sCTLA-4) as a potential biomarker for diagnosis and evaluation of the prognosis in Glioma.

Authors:  Jiajia Liu; Xiaoyi Tian; Yan Wang; Xixiong Kang; Wenqi Song
Journal:  BMC Immunol       Date:  2021-05-18       Impact factor: 3.615

8.  Developing and validating a deep learning and radiomic model for glioma grading using multiplanar reconstructed magnetic resonance contrast-enhanced T1-weighted imaging: a robust, multi-institutional study.

Authors:  Jialin Ding; Rubin Zhao; Qingtao Qiu; Jinhu Chen; Jinghao Duan; Xiujuan Cao; Yong Yin
Journal:  Quant Imaging Med Surg       Date:  2022-02

9.  circ_0030018 promotes glioma proliferation and metastasis.

Authors:  Yun Shao; Zhengxiang Yang; Weifeng Miao; Xiangrong Yu; Yiping Wu; Yi Pu
Journal:  Transl Neurosci       Date:  2021-06-09       Impact factor: 1.757

10.  Circ_CLIP2 promotes glioma progression through targeting the miR-195-5p/HMGB3 axis.

Authors:  Bing Xiao; Shi-Gang Lv; Miao-Jing Wu; Xiao-Li Shen; Wei Tu; Min-Hua Ye; Xin-Gen Zhu
Journal:  J Neurooncol       Date:  2021-08-06       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.